文献速递肺栓塞与肺血管病

系统性红斑狼疮相关肺动脉高压:法国肺动脉高压登记研究

Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry.
PubMed 文献 · Chest · 2017-08-26

基于法国肺动脉高压登记数据库,纳入经右心导管确诊的SLE相关PAH患者51例并与101例无PAH的SLE对照比较。SLE诊断至PAH诊断中位间隔4.9年,3年和5年总生存率分别为89.4%和83.9%,抗U1-RNP抗体阳性者生存显著更优(P=.04)。

要点

  • SLE-PAH患者5年总生存率为83.9%,3年为89.4%
  • 抗SSA/SSB抗体可能与PAH发生风险相关
  • 抗U1-RNP抗体阳性与生存改善相关(P=.04)

核心结论

  • SLE-PAH患者PAH诊断后5年总生存率为83.9%,抗SSA/SSB抗体可能是PAH风险因素,抗U1-RNP抗体似为生存保护因素。

研究设计与样本

  • 法国肺动脉高压登记数据库研究,纳入经右心导管确诊的SLE-PAH患者51例,并选取101例无已知PAH的SLE患者作对照。
  • 生存率采用Kaplan-Meier法估计,死亡预测因素采用Cox比例风险模型估计风险比。

主要发现

  • SLE-PAH患者与对照组在分析时点的年龄、性别及SLE病程无差异,但抗SSA和抗SSB抗体频率更高。
  • SLE诊断至PAH诊断的间隔为4.9年(范围2.8-12.9年)。
  • 3年和5年总生存率分别为89.4%(95%CI,76.2%-96.5%)和83.9%(95%CI,68.8%-92.1%)。
  • 抗U1-RNP抗体阳性患者生存率显著更优(P=.04)。

临床怎么用

  • 对SLE患者应关注PAH筛查,确诊需右心导管;抗U1-RNP抗体或有助于生存风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE). METHODS: We identified all patients with SLE and PAH (SLE-PAH) who were enrolled in the French Pulmonary Hypertension Registry with a diagnosis confirmed by right heart catheterization (RHC). A control group of 101 patients with SLE without known PAH was selected from SLE expert centers participating in the Pulmonary Hypertension Registry. Survival was estimated by the Kaplan-Meier method. Hazard ratios associated with potential predictors of death were estimated using Cox proportional hazard models. RESULTS: Of the 69 patients with SLE-PAH identified in the French Pulmonary Hypertension Registry, 51 were included in the study. They did not differ from the control group regarding age, sex, or duration of SLE at the time of the analysis but had a higher frequency of anti-SSA and anti-SSB antibodies. The delay between SLE diagnosis and PAH diagnosis was 4.9 years (range, 2.8-12.9) years. The 3- and 5-year overall survival rates were 89.4% (95% CI, 76.2%-96.5%) and 83.9% (95% CI, 68.8%-92.1%), respectively. The survival rate was significantly better in patients with anti-U1-RNP antibodies (P = .04). CONCLUSIONS: Patients with SLE-PAH have an overall 5-year survival rate of 83.9% after the PAH diagnosis. Anti-SSA/SSB antibodies may be a risk factor for PAH, and the presence of anti-U1-RNP antibodies appears to be a protective factor regarding survival.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hachulla E, Jais X, Cinquetti G, et al. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. Chest. 2017. PMID: 28851621. doi:10.1016/j.chest.2017.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。